Recent developments in the treatment and prevention of respiratory syncytial virus infection

Bibliography

• SHAY DK, HOLMAN RC, NEWMAN RD, LIU LL, STOUT JVV, ANDERSON Bronchiolitis-associated hospitalizations among US children, 1980-1996. JA/VIA (1999) 282:1440–1446
   Google Scholar
• ••Most recent and extensive overview of the epidemiology of RSV related hospitalisations in the US suggesting increase in such hospital admissions in recent years.
   Google Scholar
• HALL CB: Respiratory syncytial virus and parainfluenza virus. N Engl. I Med. (2001) 344:1917–1928.
   PubMed Web of Science ®Google Scholar
• •Recent excellent overview of RSV disease.
   Google Scholar
• HALL CB, McCARTHY CA: Respiratory sycytial virus. In: Mandell, Douglas, and BennettS Principles and Practices of Infectious Diseases, 5th edition. Mandell GL, Bennett JE, Dan R (Eds.), Philadelphia, PA, USA (2000):1782–1801.
   Google Scholar
• GLEZEN WP, TABER LH, FRANK AL, KASEL JA: Risk of primary infection and reinfection with respiratory syncytial virus. Am. Dis. Child. (1986) 140:543–546.
   PubMedGoogle Scholar
• MEISSNER CH, WELLIVER RC, CHARTRAND SA et al.: Immunoprophylaxis with palivizumab, a humanised respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants; a consensus opinion. Pediatr. Infect. Dis. (1999) 18:223-231. Review of risk factors associated with getting RSV disease in the first year of life and for developing a more severe illness when infected.
   Google Scholar
• FALSEY AR, CUNNINGHAM CK, BARKER WH et al.: Respiratory syncytial virus and influenza A infections in the hospitalized elderly. Infect. Dis. (1995) 172:389–394.
   Google Scholar
• WHIMBLEY E, GHOSH S: Respiratory syncytial infections in immunocompromised adults. Carr: Clin. Top. Infect. Dis. (2000) 20:232–255.
   PubMedGoogle Scholar
• SABLE CA, HAYDEN FG: Orthomyxoviral and paramyxoviral infections in transplant patients. Infect. Dis. Clin. North Am. (1995) 9:987–1003.
   PubMed Web of Science ®Google Scholar
• DOWELL SF, ANDERSON LJ, GARY HE JR et al.: Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. Infect. Dis. (1996) 174:456–462.
   Google Scholar
• MARTINEZ FD, WRIGHT AL, TAUSSIG LM et al.: Asthma and wheezing in the first six years of life. N Engl. Med. (1995) 332:133–138.
   PubMed Web of Science ®Google Scholar
• ••Longitudinal study of infants from birthassessing risks, including viral infections, for subsequent airway disease.
   Google Scholar
• KATTAN M: Epidemiologic evidence of increased airway reactivity in children with a history of bronchiolitis. .1 Pediatr. (1999) 135:8–13.
   Google Scholar
• SIGURS N: Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am. .1 Grit. Care Med. (2000) 61:1501–1507.
   Google Scholar
• ••Longitudinal study from Sweden studyinginfants hospitalised in infancy with RSV disease in comparison to age-matched infants not admitted and demonstrating increased wheezing and diagnosis of asthma 7.5 years later.
   Google Scholar
• HALL WJ, HALL CB, SPEERS DM: Respiratory syncytial virus infections in adults: clinical, virologic, and serial pulmonary function studies. Ann. Intern. Med. (1978) 88:203–205.
   PubMed Web of Science ®Google Scholar
• HALL CB, DOGLAS RG Jr.: Modes of transmission respiratory syncytial virus. Pediatr. (1981) 99:100–103.
   Google Scholar
• •Clinical study demonstrating that RSV is most likely transmitted by fomites and large respiratory droplets.
   Google Scholar
• COLLINS PL, MCINTOSH K, CHANOCK RIVI: Respiratory syncytial virus. In: Fields Virology (S'a Edition). BN Fields, DM Knipe, PM Howley (Eds.), Lippincott-Raven, Philadelphia, USA (1996):1313–1351.
   Google Scholar
• HALL CB, WALSH EE, SCHNABEL KC et al.: Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children.' Infect. Dis. (1990) 162:1283–1290.
   Google Scholar
• ANDERSON LJ, HEILMAN CA: Protective and disease-enhancing immune responses to respiratory syncytial virus. Infect. Dis. (1995) 171:1–7.
   Google Scholar
• WELLIVER RC: Chemokines, cytokinesand inflammatory cells in respiratory syncytial virus infection: similarities to allergic responses. Pediatr. Asthma Allergy Immunol (2000) 14:93–100.
   Google Scholar
• PIEDMONTE G, KING KA, HOLMGREN NL, BERTRAND PJ, RODRIGUEZ MM, HIRSCH RL: A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammations in rat airways. Pediatr. Res. (2000) 47:351–356.
   PubMed Web of Science ®Google Scholar
• SCHUH S, CANNY G, REISMAN JJ et al.: Nebulized albuterol in acute bronchiolitis. J. Pediatr. (1990) 117:633–637.
   PubMed Web of Science ®Google Scholar
• WANG EE, MILNER R, ALLEN U, MAJ H: Bronchodilators for treatment of mild bronchiolitis: a factorial randomised trial. Arch. Dis. Child. (1992) 67:289–293.
   PubMed Web of Science ®Google Scholar
• ADCOCK PM, SANDERS CL, MARSHALL GM: Standardizing the care of bronchiolitis. Arch. Pediatr. Adolesc. Med. (1998) 152:739–744.
   PubMed Web of Science ®Google Scholar
• •Notes the frequent use of bronchodilators in acute bronchiolitis, despite evidence that short term benefit is modest at best and that there is no evidence length of hospital stay is reduced with their use.
   Google Scholar
• MENON K, SUTCLIFFE T, KLASSEN TP: A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis. J. Pediatr. (1995) 126:1004–1007.
   PubMed Web of Science ®Google Scholar
• SANCHEZ I, DeKOSTER J, POWELL et al.: Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis. JPediatr. (1993) 122:145–151.
   PubMedGoogle Scholar
• KRISTJANSSON S, CARLSEN KCL, WENNERGREN G et al.: Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers. Arch. Dis. Child. (1993) 69:650–654.
   PubMed Web of Science ®Google Scholar
• MALHOTRA A, KRILOV LR: Influenzaand respiratory syncytial virus: Update on infection, management, and prevention. Pediatr. Clin. North Amer. (2000) 47:353–372.
   PubMed Web of Science ®Google Scholar
• CONNOLLY JH, FIELD CMB, GLASGOW JFT, SLATTERY CM, MacLYNN D: A double blind trial of prednisolone in epidemic bronchiolitis due to respiratory syncytial virus. Acta Pediatr. Scand. (1969) 58:116–120.
   PubMedGoogle Scholar
• LEER JA, GREEN IL, HEIMLICH EM: Corticosteroid treatment in bronchiolitis. Am. Dis. Child. (1969) 117:49–503.
   Google Scholar
• DABBOUS IA, TKACHYK IS, STAMM SJ: A double blind study of the effects of coricosteroids in the treatment of bronchiolitis. Pediatrics (1966) 37:477–484.
   PubMed Web of Science ®Google Scholar
• SUSSMAN S, GROSSMAN M, MAGOFFIN R, SCHIEBLE J: Dexamethasone (16-a,9-a-fluoroprednisolone) in obstructive respiratory tract infections in children. Pediatrics (1964) 34:851–855.
   PubMedGoogle Scholar
• KLASSEN TP, SUTCLIFFE T, WATTERS LK, WELLS GA, ALLEN UD, LI M: Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized controlled trial. I Pediatr. (1977) 130:191–196.
   Google Scholar
• SPRINGER C, BAR-YISHAY E, UWAYYED K, AVITAL A, VILOZNI D, GODFREY S: Corticosteroids do not affect the clinical or physiological status of infants with bronchiolitis. Pediatr. Pulmon. (1990) 9:181–185.
   PubMedGoogle Scholar
• ROOSEVELT G, SHEEHAN K, GRUPP-PHELAN J, TANZ RR, LISTERNICK R: Dexamethasone in bronchiolitis: a randomized, controlled trial. Lancet (1996) 348:292–295.
   PubMed Web of Science ®Google Scholar
• DeBOECK K, VAN DER AA N, VAN LIERDE S, CORBEEL L, EECKELLS R: Respiratory syncytial virus bronchiolitis: a double blind dexamethasone efficacy study. Pediatr. (1997) 131:919–921.
   Google Scholar
• VAN WOENSEL JB, WOLFS TF, VAN AALDEREN WM, BRAND PL, KIMPEN 447 Expert Op/n. Ther. Patents (2002) 12(3) JL: Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiloitis. Thorax (1997) 52:634–637.
   Google Scholar
• GIDEON P, DEKEL, B, VARDI A, SZEINBERG A, LOTAN D, BARZILAY Z: Heliox in respiratory failure secondary to bronchiolitis: a new therapy. Pediatr. Pulmon. (1996) 22322–323.
   Google Scholar
• HOLLMAN G, SHEN G, ZENG L et al: Helium-oxygen improves clinical asthma scores in children with acute bronchiolitis. Crit. Care Med. (1998) 26:1731–1736.
   PubMed Web of Science ®Google Scholar
• NAVAS L, WANG E, DE CARVALHO V et al.: Improved outcome of respiratory syncytial virus in a high-risk hospitalized population of Canadian children. J. Pediatr. (1992) 121:348–354.
   Google Scholar
• HAYDEN FG. Antiviral agents. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics Oh Edition). JG Hardman, LE Limbird, PB Molinoff, RW Ruddon, AG Gilman (Eds.), McGraw-Hill, New York, USA (1996):1191–1223.
   Google Scholar
• HALL CB, MCBRIDE JT, WALSH EE: Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection. N Engl. J. Med. (1983) 318:1443–1447.
   Google Scholar
• BARRY W, COCKBURN F, CORNALL R et al.: Ribavirin aerososl for acute bronchiolitis. Arch. Dis. Child. (1986) 61:593–597.
   PubMedGoogle Scholar
• HALL CB, MCBRIDE IT, GALA CL et al:Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA (1985) 254:3047–3051.
   PubMed Web of Science ®Google Scholar
• GROOTHUIS JR, WOODIN KA, KATZ R et al: Early ribavirin treatment of respiratory syncytial virus infection in high-risk children. Pediatr. (1990) 117:792–798.
   Google Scholar
• SMITH DW, FRENKEL LR, MATHERS LH et al.: A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl. J. Med. (1991) 432:24–29.
   Google Scholar
• MEERT KL, SARNAIL AP, GELMINI MJ,LIEH-LAI MW: Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: prospective, double-blind, randomized trial. Crit. Care Med. (1994) 22:566–572.
   PubMed Web of Science ®Google Scholar
• FERGIE JE: Effects of ribavirin therapy on RSV infections in high-risk infants and young children 2 years after hospitalization. In: RSV and asthma: Is there a link.TW Hiatt (Ed.), American Thoracic Society, New York, USA (1998):43–45.
   Google Scholar
• ROSNER IK, WELLIVER RC, EDELSON PJ, GERACI-CIARDULIO K, SUN M.: Effect of ribavirin therapy on respiratory syncytial virus-specific IgE and IgA responses after infection. J. Infect. Dis. (1987) 155:1043–1047.
   Google Scholar
• EDELL DS, BRUCE E, HALE K et al: Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus with ribavirin in previously healthy infants: a preliminary report. Pediatr. Pulmonl (1998) 25:154–158.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ WJ, ARROBIO J, FINK R et al.: Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis. Arch. Pediatr. Adolesc. Med. (1999) 153:469–474.
   PubMed Web of Science ®Google Scholar
• KRILOV LR, MANDEL FS, BARONE SR et al.: Follow-up of children with respiratory syncytial virus lower respiratory tract infection in 1986 and 1987: Potential effect of ribavirin on long-term pulmonary function. The bronchiolitis study group. Pediatr. Infect. Dis. J. (1997) 16:273–276.
   PubMed Web of Science ®Google Scholar
• LONG CE, VOTER KZ, BARKER WH, HALL CB: Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory infection and randomly treated with ribavirin or placebo. Pediatr. Infect. Dis. J. (1997) 16:1023–1028.
   PubMed Web of Science ®Google Scholar
• AMERICAN ACADEMY OF PEDIATRICS: Respiratory syncytial virus. In: 2000 Red Book: Report of the Committee on Infectious Diseases, 25th Edition. Pickering LK (Ed.), Elk Grove Village, IL, USA (2000)483–487.
   Google Scholar
• SIMOES EAF, GROOTHUIS JR, TRISTAM DA et al.: Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J. Pediatr. (1996) 129:214–219.
   PubMedGoogle Scholar
• SIMOES EAF, SONDHEIMER HM, TOP FH JR: Respiratory syncytial immune globulin for prophylaxis against respiratory syncytial disease in infants an children with congenital heart disease: The cardiac study group. J. Pediatr. (YEAR) 133:492–499.
   Google Scholar
• PRINCE GA: An update on respiratory syncytial virus antiviral agents. Expert Opin. Investig. Drugs (2001) 10(2):297–308.
   PubMed Web of Science ®Google Scholar
• PRINCE GA, MATHEWS A, CURTIS S, PORTER DD: Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model using systemically administered monoclonal antibody (palivizumab) and glucocorticoid. J. Infect. Dis. (2000) 182:1326–1330.
   Web of Science ®Google Scholar
• KAPIKIAN AZ, MITCHELL RH, CHANOCK RM, SHVEDOFF RA, STEWART CE: An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS vaccine. Am. J. Epidemiol (1969) 89:405–421.
   PubMed Web of Science ®Google Scholar
• KIM HW, CANCHOLA JG, BRANDT CD et al.: Respiratory syncytial virus disease in infants despite of prior administration of antigenic inactivated vaccine. Am. J. Epidemiol (1969) 89:422–434.
   PubMed Web of Science ®Google Scholar
• MURPHY BR, PRINCE GA, WALSH EE et al.: Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. Clin. Microbiol (1986) 24:197–202.
   Google Scholar
• KIM HW, LEIKIN SL, ARROBIO J, BRANDT CD, CHANOCK RIVI, PARROTT RH: Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or infection. Pediatr. Res. (1976) 10:75–78.
   PubMed Web of Science ®Google Scholar
• PRINCE GA: Respiratory syncytial virus antiviral agents. Expert Opin. Ther. Patents. (1999) 9(6):753–762.
   Web of Science ®Google Scholar
• KIM GS, JUDD DA, HILL CL, SCHINAZI RF: Synthesis, characterization and biological activity of a new potent class of anti-HIV agents, the peroxoniobium-substitued heterpolytungstates. J. Med. Chem. (1994) 37:816–820.
   PubMed Web of Science ®Google Scholar
• BARNARD DL, HILL CL, GAGE T et al: Potent inhibition of respiratory syncytial virus by polyoxometalates of several structure classes. Antiviral. Res. (1997) 34:27–37.
   PubMed Web of Science ®Google Scholar
• SHIGETA S: Recent progress in antiviralchemotherapy for respiratory syncytial virus infections. Expert Opin. Investig. Drugs (2000) 9(2):221–235.
   PubMed Web of Science ®Google Scholar
• SHIGETA S, MORI S, WATANBE J, YAMASE T, SCHINAZI RF: In vitro anti-myxovirus activity and mechanism of anti-influenza activity of poloxometalates PM-504 and PM-523. Antivir: Chem. Chemother: (1996) 7:346-352.448 Expert Opin. Ther. Patents (2002)12(3)
   Google Scholar
• SCHINAZI RF: Poloxometalates in Medicine. Chem. Rev (1998) 98:327–358.
   PubMedGoogle Scholar
• ••Excellent review of polyoxometalatecompounds and their potential use in medicine, including agents with anti-viral activity.
   Google Scholar
• KIMURA K, MORI S, TOMITA K et al.: Antiviral activity of NMS03 against respiratory syncytial virus infection in vitro and in vivo. Antiviral Res. (2000) 47:41–51.
   PubMed Web of Science ®Google Scholar
• SHIGETA S, MORI S, BABA M et al.: Antiviral activities of ribavirin, 5-ethyny1-1-3-D-ribofuranosy1imidazo1e-4-carboxamide and 6'-(R)-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob. Agents Chemother. (1992) 36:435–439.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E, COOLS M, BALZARINI J et al.: Antiviral activities of 5-ethyny1-1-13-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agency Chemother. (1991) 35:679–684.
   PubMed Web of Science ®Google Scholar
• KOSUGI Y, SAITO Y, MORI S, WATANABE J, BABA M, SHIGETA S: Antiviral activities of mizoribine and other inosine monophosphate dehydrogenase inhibitors against several ortho- and paramyxoviruses. Antivir. Chem. Chemother. (1994) 5:366–371.
   Web of Science ®Google Scholar
• MARKLAND W, MCQUAID TJ, JAIN J, KWONG AD: Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with a-interferon. Antimicrob. Agents Chemother. (2000) 44:859–866.
   PubMed Web of Science ®Google Scholar
• WRIGHT T, SHIFFMAN ML, KNOX S, ETTE E, KAUFFMAN RS, ALAM J: Dose-ranging study of VX-497, a novel, oral IMPDH inhibitor, in patients with hepatitis C. Hepatology (1999) 30(suppl.):122A.
   Google Scholar
• WATANABE W, SUDO K, SATO R et al.: Novel anti-respiratory syncytial (RS) viral compounds: benzodithin derivatives. Biochem. Biophys. Res. Comm. (1998) 249:922–926.
   PubMed Web of Science ®Google Scholar
• ••Excellent description of benzodithin agentswith in vitro anti-RSV activity.
   Google Scholar
• MALLEY R, DEVINCENZO J, RAMILO 0, DENNEHY PH, MEISSNER HC, GRUBER WC et al: Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.J. Infect. Dis. (1998) 178:1555–1561.
   PubMed Web of Science ®Google Scholar
• CROWE JE Jr.: Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (Ply). Vaccine (1995) 13:415–421.
   PubMedGoogle Scholar
• CROWE JE JR, PHUONG TB, DAVIS AR et al.: A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus (RSV cpts-248) retains immunogenecity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine (1994) 12:783–790.
   PubMedGoogle Scholar
• DUDAS RA, KARRON RA: Respiratory syncytial virus vaccines. Clin. Microbial. Rev (1998) 11:430–439.
   PubMed Web of Science ®Google Scholar
• •Extensive discussions of recent approaches to development of RSV vaccines.
   Google Scholar
• OEIN NL, BRIDEAU RJ, WALSH EE et al.: Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine (1995) 12:731–735.
   Google Scholar
• PIEDRA PA, GRACE S, JEWELL A et al.: Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. j (1996) 15:23–31.
   PubMed Web of Science ®Google Scholar
• MCCARTHY CA, HALL CB: Recent approaches to the management and prevention of respiratory syncytial virus infection. Curl: Clin. Top. Infect. Dis. (1998) 18:1–18.
   PubMedGoogle Scholar
• ENGLUND J, GLEZEN WP, PIEDRA PA: Maternal immunization against viral disease. Vaccine (1998) 16:1456–1463.
   PubMed Web of Science ®Google Scholar
• COLLINS PL, WHITEHEAD S, BUKREYEV A et al: Recombinant live attenuated RSV vaccines. Presented at the RSV after 45 Years Symposium, Segovia, Spain, October lst-3rd, (2001) Abstract.
   Google Scholar
• COLLINS PL, HILL MG, CAMARGO E, GROSFELD H, CHANOCK RIVI, MURPHY BR: Production of infectious human respiratory syncytial virus from cloned eDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. (1998) 92:11563–11567.
   Google Scholar